YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Elutia Inc. Boston Scientific released the full $8 million holdback on schedule and with no claims Escrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan facility…
Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 5:00 p.m. ET CALL PARTICIPANTS Chief Executive Officer - Randy Mills Chief Financial Officer - Matthew Ferguson Full Conference Call Transcript Operator: Good day, and thank yo…
Elutia Inc. Q2 2026 Earnings Call Summary - Moby Strategic Pivot to High-Value Reconstruction Market Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 p…
Earnings Call Insights: Elutia (ELUT) Q2 2026 MANAGEMENT VIEW * "Four things defined this quarter. First, we're funded. Up to $26 million of additional capital with no equity offering, we believe that carries us through the NXT-41x clearan…
GAITHERSBURG, Md., July 31, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2026 financial results a…
(RTTNews) - This week, the healthcare sector saw multiple U.S FDA and European Commission approvals, strategic licensing and M&A activity, as well as pivotal clinical trial readouts and regulatory setbacks. Positive data readouts spanned m…
(RTTNews) - Elutia Inc. (ELUT) announced the signing of a definitive agreement to sell its SimpliDerm human acellular dermal matrix business to Cellution Biologics Inc. for total consideration of up to $11 million. As per the transaction a…
NEW YORK, NY / ACCESS Newswire / March 18, 2026 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day March Small-Cap Virtual Investor Conference taking place Wedne…
This article first appeared on GuruFocus. Revenue: $3.3 million for Q4 2025, up 16% from $2.8 million in Q4 2024. Gross Margin: Adjusted gross margin of 66.8% for Q4 2025, up from 56.5% in Q4 2024. Net Loss from Continuing Operations: $6.5…
Earnings Call Insights: Elutia Inc. (ELUT) Q4 2025 MANAGEMENT VIEW * CEO C. Mills opened the call by emphasizing the company's mission to "humanize medicine so patients can thrive without compromise" and highlighted the significant unmet n…
Elutia Inc. Q4 2025 Earnings Call Summary - Moby Strategic Shift and Operational Context Management is transitioning the company to focus exclusively on drug-eluting biologics, specifically targeting the high infection rates in breast reco…
(RTTNews) - Biotech and healthcare names were among the notable movers in Wednesday's after-hours trading session, with several small-cap companies posting strong gains on the back of corporate updates and investor momentum. Plus Therapeut…
Elutia Inc. Fourth quarter revenue up 16% year-over-year, $26.9M of secured debt eliminated, and total cash and escrowed proceeds of $44.3M at year-end GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Eluti…
(RTTNews) - Several biotechnology and life sciences companies posted notable gains in after-hours trading on Friday, reflecting investor interest in recent clinical and corporate developments. Kura Oncology, Inc. (KURA) led the group with…
(RTTNews) - The after-hours market delivered a mixed but generally positive tone on Tuesday evening, with several small- and mid-cap names posting modest gains. One biotech, however, stole the spotlight with a dramatic surge following majo…
Elutia's stock narrative has shifted following analysts' latest reassessment, following the company's recent strategic divestiture. While the fair value estimate remains steady, a slight increase in the discount rate signals cautious senti…
Over the past several years, Boston Scientific BSX has pursued a series of acquisitions in support of its growth strategy, both strengthening its core businesses and expanding into high-growth adjacent markets. The latest is the asset acqu…
Earnings Call Insights: Elutia Inc. (ELUT) Q3 2025 MANAGEMENT VIEW * CEO C. Mills emphasized Elutia's mission of "humanizing medicine so that patients can thrive without compromise," spotlighting the company's strategic focus on breast rec…
Elutia Inc. - Rapidly advancing NXT-41x to address significant unmet medical need for plastic and reconstructive surgery, which represents an estimated $1.5 billion U.S. market opportunity Conference call today at 5:00 p.m. ET / 2:00 p.m.…
GAITHERSBURG, Md., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its third quarter 2025 financial results af…
GAITHERSBURG, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the…
Industry leader brings 40 years of executive and board experience across the global medical technology sector GAITHERSBURG, Md., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-el…
Elutia Inc. - Strengthened balance sheet to fully fund development and launch of NXT-41 platform - - Biologics for breast reconstruction represents $1.5 billion U.S. total addressable market - GAITHERSBURG, Md., Oct. 01, 2025 (GLOBE NEWSWI…
- Strengthened balance sheet to fully fund development and launch of NXT-41 platform - - Biologics for breast reconstruction represents $1.5 billion U.S. total addressable market - GAITHERSBURG, Md., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Eluti…
(RTTNews) - Several biotech names posted notable after-hours gains on Tuesday, driven by clinical trial updates, fresh funding announcements, and upcoming product showcases. From gene editing breakthroughs to Alzheimer's trial enrollment,…
A major leadership change can quickly shift the conversation around a stock, and that is exactly what we have with Boston Scientific (BSX) this week. With news that Jeffrey B. Mirviss, Executive Vice President and President of Peripheral I…
Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index and the Health Care Selec PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
* Elutia (NASDAQ:ELUT [https://seekingalpha.com/symbol/ELUT]) said on Tuesday that it has entered into a definitive agreement to sell its EluPro and CanGaroo bioenvelopes, designed to protect patients receiving implantable medical devices,…
Elutia Inc. - Transaction affirms the strength of Elutia’s proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction - - Company to provide update at the H.C. Wainwright 27th Annual Global I…
- Transaction affirms the strength of Elutia’s proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction - - Company to provide update at the H.C. Wainwright 27th Annual Global Investment Co…
Earnings Call Insights: Elutia Inc. (ELUT) Q2 2025 MANAGEMENT VIEW * CEO C. Randal Mills highlighted the ongoing commercial success of EluPro, reporting "49% sequential growth this quarter over last quarter built on the back of 7 national…
Aleutia reported its Q2 2025 earnings, revealing a mixed performance with a loss per share of $0.26, missing the forecasted $0.19 loss. Revenue for the quarter came in at $6.3 million, falling short of the $7.8 million expectation. Despite…
* Elutia press release [https://seekingalpha.com/pr/20201874-elutia-delivers-robust-growth-on-the-strength-of-elupro-market-adoption] (NASDAQ:ELUT [https://seekingalpha.com/symbol/ELUT]): Q2 GAAP EPS of -$0.23. * Revenue of $6.3M. MORE ON…
Investing.com - Elutia (NASDAQ: ELUT) reported second quarter EPS of $-0.260, $0.07 worse than the analyst estimate of $-0.190. Revenue for the quarter came in at $6.26M versus the consensus estimate of $7.8M. Elutia’s stock price closed a…
Elutia Inc. EluPro™ Q2 revenue up 49% sequentially; Elutia advances next-generation drug-eluting biomatrix for breast reconstruction Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) --…
GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Michelle LeRoux Williams, Chief Scientific Officer, has…